ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria Fundación Jiménez Díaz (12)
2017
2016
-
C-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer
Molecular Cancer Therapeutics, Vol. 15, Núm. 11, pp. 2780-2790
-
FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth
Nature Communications, Vol. 7
-
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
American Journal of Cancer Research, Vol. 6, Núm. 11, pp. 2661-2678
-
Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
British Journal of Cancer, Vol. 115, Núm. 3, pp. 322-331
2015
-
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Journal of the National Cancer Institute, Vol. 107, Núm. 12
-
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
Oncotarget, Vol. 6, Núm. 6, pp. 4299-4314
-
Snail1-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis
Cancer Research, Vol. 75, Núm. 2, pp. 284-295
2014
-
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
Oncotarget, Vol. 5, Núm. 1, pp. 196-210
-
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer
European Journal of Cancer, Vol. 50, Núm. 15, pp. 2725-2734
2012
-
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Annals of Oncology, Vol. 23, Núm. 5, pp. 1156-1164